Study suggests glucagon-like peptide-1 receptor agonists related to adolescent weight loss

February 4, 2013

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics.

GLP-1 receptor agonist therapy, approved for adults with , reduces body weight by enhancing satiety and suppressing appetite, even in patients without diabetes, according to the study background.

Aaron S. Kelly, Ph.D., of the University of Minnesota Medical School, Minneapolis, and colleagues conducted a three-month, placebo-controlled trial followed by a three-month open-label extension during which medication was offered to all patients. A total of 22 patients (12 to 19 years of age) completed the trial, in which the medication exenatide was administered subcutaneously (injected).

"The results of this clinical trial extend the findings of our previous pilot and feasibility study and offer additional evidence, within the context of a randomized, placebo-, that treatment with a GLP-1 receptor agonist significantly reduces BMI and body weight in adolescents with severe obesity," the authors note.

Exenatide caused a greater reduction in BMI compared with placebo (-2.7 percent). Researchers also observed a further reduction in BMI during the open-label phase for those patients initially randomized to exenatide (cumulative BMI reduction of 4 percent). The medication also resulted in a reduction, on average, in systolic blood pressure of -6mm HG, although researchers note it did not reach the level of statistical significance.

"In conclusion, data from the current study provide evidence that GLP-1 receptor agonist treatment reduces BMI and elicits a potentially meaningful reduction in SBP in adolescents with severe obesity," the authors conclude.

Explore further: Gut hormone leads to weight loss in overweight or obese patients

More information: JAMA Pediatr. Published online February 4, 2013. doi:10.1001/jamapediatrics.2013.1045

Related Stories

Metformin treatment beneficial for obese children, teens

December 21, 2012

(HealthDay)—Obese children and adolescents treated with twice-daily metformin have significantly improved body mass index standard deviation scores (BMI-SDS), fasting glucose, and other metabolic risk factors, according ...

Recommended for you

Youth dance classes score low in physical activity

May 18, 2015

For parents who send their kids to dance classes to get some exercise, a new study from researchers at University of California, San Diego School of Medicine suggests most youth dance classes provide only limited amounts ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.